Diabetes Mellitus, Type 2NCT05787457
Comparative Metabolomics in Diabetes Patients From Sri Lanka and Switzerland
An observational study of Diabetes Mellitus, Type 2, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
Trial summary
This study is a case-control study, where the assumed different subtypes of type 2 diabetes in people of Tamil ethnicity and Swiss origin living in Bern, Switzerland will be examined by measuring the metabolite profiles and the corresponding genetic background as well as ethnic differences in fat distribution… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Clinical examination, Blood testing and MRI
- How many people
- 34 participants
- Where
- 1 siteSwitzerland
- Study dates
- 31 Jul 2014to 30 Sep 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of thirty Tamils and sixty native Swiss people with type 2 diabetes.
Who may be able to join
- Diagnosed with type 2 diabetes per WHO criteria.
- Swiss ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Switzerland)
- Tamil ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Sri Lanka, belonging to ethnic identity of Tamils, respectively)
- Age limit: 18 - 75 years
Who cannot join
- Subjects with type 1 diabetes, steroid-induced diabetes, gestation diabetes, or pancreoprivic diabetes.
- Subjects with pregnancy.
- Subjects with metal implant, tattoos, or claustrophobia. MRI must be feasible.
- Subjects with severe chronic diseases, e.g. malignancies, heart or renal diseases (> stage 3).
- Subjects not able to provide informed consent.
- Enrolled in another study.
Trial locations and contacts
1 site in 1 country.
About this study
This study is a case-control study, where the assumed different subtypes of type 2 diabetes in people of Tamil ethnicity and Swiss origin living in Bern, Switzerland will be examined by measuring the metabolite profiles and the corresponding genetic background as well as ethnic differences in fat distribution performed by magnetic resonance imaging (MRI). The investigators aim to show that the specific metabolite profile and the fat distribution in the Tamil population is associated with the high prevalence of diabetes in this ethnicity. Fat distribution patterns are thought to determine the expression and severity of dysglycaemia. Additionally, the investigators aim to identify the key enzymes, their corresponding genes, and the respective polymorphisms relevant for these metabolic variations.
Read the detailed description
Over the last two decades, the prevalence of type 2 diabetes has exploded among native and migrant South Asian populations. The earliest available epidemiological study in a rural sector in Sri Lanka showed a diabetes prevalence of 2.5% in 1990. In 2008 the Sri Lanka Diabetes, Cardiovascular Study (SLDCS) reported a prevalence of 10.3% for Sri Lankans aged ≥ 20 years. South Asian migrants living in western countries have higher diabetes prevalence rates compared with indigenous populations, around 10-14% in Europeans, 25-34% in Indian Asians. Moreover, type 2 diabetes develops at younger age in Asians than in Caucasian populations. In the UK the relative risk of type 2 diabetes in South Asian children is 14 times greater than in children of European descent.
A popular hypothesis for the greater prevalence of type 2 diabetes is that South Asians are undergoing rapidly changes in demographic profile, increasing urbanization and development and adoption of modern ("westernized") lifestyle. Nutrition transition, adoption of a sedentary lifestyle, reduced physical activity and possibly mental and social stress are held responsible for this increase. Especially the effect of dietary changes with higher intakes of sugars, animal fats and vegetable oils is large and most of the emerging epidemic of chronic disorders, like diabetes mellitus, are diet related. It has been detected that obesity induces excess lipolysis causing increased concentration of non-esterified fatty acids and triglycerides in blood and skeletal muscle. Lipotoxicity plays an important role in inducing insulin resistance and β-cell damage. Furthermore it has been observed that the kind of fat distribution correlates with the expression and the severity of dysglycaemia and that there are marked ethnic differences in fat distribution.
For example people of both South Asian and African Caribbean descent have an elevated risk of diabetes compared to Europeans. But while South Asians are centrally obese, dyslipidaemic and vulnerable to cardiac disease, African Caribbeans do not exhibit the diabetes related dyslipidaemic profile. A potential explanation for this discrepancy may lie in ethnic differences in fat distribution.
But it is not clear whether this can completely be attributed to ethnic differences, because features of insulin resistance, hypertriglyceridaemia, and hyperinsulinaemia are seen even in non-obese South Asian individuals. In contrast to Caucasian diabetic patients having a much higher BMI than the nondiabetic Caucasian population, the average BMI of Asians with diabetes is similar to the non-diseased population, indicating that South Asians diabetic patients in average are not obese. South Asians, however, have a much greater tendency to deposit intra-abdominal fat, which is metabolically active and strongly related to insulin resistance. Furthermore South Asians are proportionally fat due to less non-fat tissues. Therefore, insulin resistance in people of South Asian origin can occur even in the absence of conventionally defined obesity. The development of type 2 diabetes linked to obesity caused by overnutrition, which is regarded as a common feature in the Caucasian population, may not be typical in South Asians. This points at the limitations of BMI as a measure of adiposity across populations. These specific clinical characteristics, including a high degree of insulin resistance associated with abdominal fat deposition without massive obesity are common in patients of South Asian descent.
These findings suggest that Asians are more vulnerable than other ethnic groups to type 2 diabetes in response to a relatively small increase in body weight. Genetic susceptibility may be responsible for high prevalence of insulin resistance in South Asians . Such an escalating prevalence of type 2 diabetes is unlikely to be explained by genetic factors, indicating a greater influence of environmental factors in disease aetiology. Nevertheless type 2 diabetes has a strong genetic component. Most Asian diabetes patients have first-degree relative with diabetes. Several genetic variants have been identified by genome-wide association studies. Most genetic variants linked to type 2 diabetes seem to be related to insulin secretion rather than insulin resistance. In South Asian populations, however, the burden is the increased susceptibility to develop insulin resistance due to genetic predisposition and/or in response to certain environmental influences. These findings are showing the need for populations-specific studies. For this reason, the investigators restrict the study to the Tamil ethnic group living in Bern, Switzerland, with a Swiss reference cohort. The Tamil ethnicity is an isolated population with high prevalence of type 2 diabetes. Cultural customs have preserved this population from ethnic admixture. The first and the most of the second generation of migrated Tamils still belong to a population with a homogeneous genetic background, which facilitate to identify complex trait-susceptibility genes.
In contrast to many previous genome-wide association studies an inverse approach is taken for this study. The primary objective of this study is to show changes in the metabolic concentrations in plasma between Tamil individuals and native Swiss population using a mass-spectrometric approach. Type 2 diabetics have specific metabolic variations, and the investigators assume that South Asians and Caucasians differ in these alterations. The secondary aim of this study is to identify the key enzymes, their corresponding genes, and the respective polymorphisms relevant for the metabolic variations using a metabolic-pathway-based search including also intronic variants commonly missed by SNP (single nucleotide polymorphism)-and haplotype-analysis.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Clinical examination, Blood testing, MRI
- Keywords
- Native South Asian population, Migrant South Asian population, Swiss ethnicity, Tamil ethnicity, Body fat distribution, Type 2 Diabetes, Magnetic resonance imaging, Genetic predisposition, Genetic background, Metabolomics, Non-targeted mass spectrometry, Insulin resistance, Hypertriglyceridaemia, Hyperinsulinaemia
- Medical subject headings
- Diabetes Mellitus, Type 2, Genetic Predisposition to Disease, Insulin Resistance, Hypertriglyceridemia, Hyperinsulinism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical examinationOther
Blood testingOther
MRIOther
| Study group | Role | What they receive |
|---|---|---|
| Tamil natives with Diabetes Type 2 | Thirty Tamil natives (15 men, 15 women), representing general Tamil diabetic cohort. Receives: Other: Clinical examination; Other: Blood testing; Other: MRI | |
| Swiss natives with Diabetes Type 2_matched | Thirty Swiss natives (15 men, 15 women) matching the Tamil cohort. Receives: Other: Clinical examination; Other: Blood testing; Other: MRI | |
| Swiss natives with Diabetes Type 2_not matched | Thirty Swiss natives (15 men, 15 women), who are not matched to the Tamil cohort, representing general Swiss diabetic cohort. Receives: Other: Clinical examination; Other: Blood testing; Other: MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Metabolic phenotype of type 2 diabetes mellitus across groups
Significant metabolic changes in blood plasma of type 2 diabetic patients compared across groups as quantified by mass-spectrometric analysis
Measured: At baseline
Secondary outcomes (1)
Genetic Differences
Frequency of single nucleotide polymorphisms across groups
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2023
- Study start31 Jul 2014
- Primary completion30 Sep 2021
- Study completion30 Sep 2021
Why it stopped: Insufficient recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- More trials run by Insel Gruppe AG, University Hospital BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Martin Fiedler, MD, MBA, Principal investigator, Insel Gruppe AG, University Hospital Bern
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05787457
- Sponsor's protocol ID
- KEK-203/13
- Other IDs
- 2527
- Status last verified
- Mar 2023
- First submitted
- 20 Apr 2016
- Last updated
- 28 Mar 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Sharing data depends on institutional (sponsor) and ethics agreement.
Publications
Abate N, Carulli L, Cabo-Chan A Jr, Chandalia M, Snell PG, Grundy SM. Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. J Clin Endocrinol Metab. 2003 Dec;88(12):5927-34. doi: 10.1210/jc.2003-030453.
PubMed 14671192Barnett AH, Dixon AN, Bellary S, Hanif MW, O'hare JP, Raymond NT, Kumar S. Type 2 diabetes and cardiovascular risk in the UK south Asian community. Diabetologia. 2006 Oct;49(10):2234-46. doi: 10.1007/s00125-006-0325-1. Epub 2006 Jul 18.
PubMed 16847701Ehtisham S, Crabtree N, Clark P, Shaw N, Barrett T. Ethnic differences in insulin resistance and body composition in United Kingdom adolescents. J Clin Endocrinol Metab. 2005 Jul;90(7):3963-9. doi: 10.1210/jc.2004-2001. Epub 2005 Apr 19.
PubMed 15840754Illangasekera U, Nugegoda DB, Perera LS. Prevalence of diabetes mellitus and impaired glucose tolerance in a rural Sri Lankan community. Ceylon Med J. 1993 Sep;38(3):123-6.
PubMed 7828231Illangasekera U, Rambodagalla S, Tennakoon S. Temporal trends in the prevalence of diabetes mellitus in a rural community in Sri Lanka. J R Soc Promot Health. 2004 Mar;124(2):92-4. doi: 10.1177/146642400412400214.
PubMed 15067982Jourdan C, Petersen AK, Gieger C, Doring A, Illig T, Wang-Sattler R, Meisinger C, Peters A, Adamski J, Prehn C, Suhre K, Altmaier E, Kastenmuller G, Romisch-Margl W, Theis FJ, Krumsiek J, Wichmann HE, Linseisen J. Body fat free mass is associated with the serum metabolite profile in a population-based study. PLoS One. 2012;7(6):e40009. doi: 10.1371/journal.pone.0040009. Epub 2012 Jun 27.
PubMed 22761945Katulanda P, Constantine GR, Mahesh JG, Sheriff R, Seneviratne RD, Wijeratne S, Wijesuriya M, McCarthy MI, Adler AI, Matthews DR. Prevalence and projections of diabetes and pre-diabetes in adults in Sri Lanka--Sri Lanka Diabetes, Cardiovascular Study (SLDCS). Diabet Med. 2008 Sep;25(9):1062-9. doi: 10.1111/j.1464-5491.2008.02523.x.
PubMed 19183311Katulanda P, Sheriff MH, Matthews DR. The diabetes epidemic in Sri Lanka - a growing problem. Ceylon Med J. 2006 Mar;51(1):26-8. doi: 10.4038/cmj.v51i1.1373.
PubMed 16898034Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010 Jan 30;375(9712):408-18. doi: 10.1016/S0140-6736(09)60937-5. Epub 2009 Oct 28.
PubMed 19875164Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes. 2001 Feb;50 Suppl 1:S118-21. doi: 10.2337/diabetes.50.2007.s118.
PubMed 11272168Vandenheede H, Deboosere P, Stirbu I, Agyemang CO, Harding S, Juel K, Rafnsson SB, Regidor E, Rey G, Rosato M, Mackenbach JP, Kunst AE. Migrant mortality from diabetes mellitus across Europe: the importance of socio-economic change. Eur J Epidemiol. 2012 Feb;27(2):109-17. doi: 10.1007/s10654-011-9638-6. Epub 2011 Dec 14.
PubMed 22167294
Study at a glance
From the registry record, last updated by the sponsor on 28 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Metabolomics in Diabetes Patients From Sri Lanka and Switzerland
- ClinicalTrials.gov ID
- NCT05787457
- Acronym / sponsor ID
- KEK-203/13
- Conditions
- Diabetes Mellitus, Type 2
- Keywords
- Native South Asian population, Migrant South Asian population, Swiss ethnicity, Tamil ethnicity, Body fat distribution, Type 2 Diabetes, Magnetic resonance imaging, Genetic predisposition
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Insufficient recruitment
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Insel Gruppe AG, University Hospital BernUniversity, hospital or other
- Study start
- 31 Jul 2014 (actual)
- Primary completion
- 30 Sep 2021 (actual)
- Study completion
- 30 Sep 2021 (actual)
- First posted
- 28 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a case-control study, where the assumed different subtypes of type 2 diabetes in people of Tamil ethnicity and Swiss origin living in Bern, Switzerland will be examined by measuring the metabolite profiles and the corresponding genetic background as well as ethnic differences in fat distribution performed by magnetic resonance imaging (MRI). The investigators aim to show that the specific metabolite profile and the fat distribution in the Tamil population is associated with the high prevalence of diabetes in this ethnicity. Fat distribution patterns are thought to determine the expression and severity of dysglycaemia. Additionally, the investigators aim to identify the key enzymes, their corresponding genes, and the respective polymorphisms relevant for these metabolic variations.
Detailed description
Over the last two decades, the prevalence of type 2 diabetes has exploded among native and migrant South Asian populations. The earliest available epidemiological study in a rural sector in Sri Lanka showed a diabetes prevalence of 2.5% in 1990. In 2008 the Sri Lanka Diabetes, Cardiovascular Study (SLDCS) reported a prevalence of 10.3% for Sri Lankans aged ≥ 20 years. South Asian migrants living in western countries have higher diabetes prevalence rates compared with indigenous populations, around 10-14% in Europeans, 25-34% in Indian Asians. Moreover, type 2 diabetes develops at younger age in Asians than in Caucasian populations. In the UK the relative risk of type 2 diabetes in South Asian children is 14 times greater than in children of European descent.
A popular hypothesis for the greater prevalence of type 2 diabetes is that South Asians are undergoing rapidly changes in demographic profile, increasing urbanization and development and adoption of modern ("westernized") lifestyle. Nutrition transition, adoption of a sedentary lifestyle, reduced physical activity and possibly mental and social stress are held responsible for this increase. Especially the effect of dietary changes with higher intakes of sugars, animal fats and vegetable oils is large and most of the emerging epidemic of chronic disorders, like diabetes mellitus, are diet related. It has been detected that obesity induces excess lipolysis causing increased concentration of non-esterified fatty acids and triglycerides in blood and skeletal muscle. Lipotoxicity plays an important role in inducing insulin resistance and β-cell damage. Furthermore it has been observed that the kind of fat distribution correlates with the expression and the severity of dysglycaemia and that there are marked ethnic differences in fat distribution.
For example people of both South Asian and African Caribbean descent have an elevated risk of diabetes compared to Europeans. But while South Asians are centrally obese, dyslipidaemic and vulnerable to cardiac disease, African Caribbeans do not exhibit the diabetes related dyslipidaemic profile. A potential explanation for this discrepancy may lie in ethnic differences in fat distribution.
But it is not clear whether this can completely be attributed to ethnic differences, because features of insulin resistance, hypertriglyceridaemia, and hyperinsulinaemia are seen even in non-obese South Asian individuals. In contrast to Caucasian diabetic patients having a much higher BMI than the nondiabetic Caucasian population, the average BMI of Asians with diabetes is similar to the non-diseased population, indicating that South Asians diabetic patients in average are not obese. South Asians, however, have a much greater tendency to deposit intra-abdominal fat, which is metabolically active and strongly related to insulin resistance. Furthermore South Asians are proportionally fat due to less non-fat tissues. Therefore, insulin resistance in people of South Asian origin can occur even in the absence of conventionally defined obesity. The development of type 2 diabetes linked to obesity caused by overnutrition, which is regarded as a common feature in the Caucasian population, may not be typical in South Asians. This points at the limitations of BMI as a measure of adiposity across populations. These specific clinical characteristics, including a high degree of insulin resistance associated with abdominal fat deposition without massive obesity are common in patients of South Asian descent.
These findings suggest that Asians are more vulnerable than other ethnic groups to type 2 diabetes in response to a relatively small increase in body weight. Genetic susceptibility may be responsible for high prevalence of insulin resistance in South Asians . Such an escalating prevalence of type 2 diabetes is unlikely to be explained by genetic factors, indicating a greater influence of environmental factors in disease aetiology. Nevertheless type 2 diabetes has a strong genetic component. Most Asian diabetes patients have first-degree relative with diabetes. Several genetic variants have been identified by genome-wide association studies. Most genetic variants linked to type 2 diabetes seem to be related to insulin secretion rather than insulin resistance. In South Asian populations, however, the burden is the increased susceptibility to develop insulin resistance due to genetic predisposition and/or in response to certain environmental influences. These findings are showing the need for populations-specific studies. For this reason, the investigators restrict the study to the Tamil ethnic group living in Bern, Switzerland, with a Swiss reference cohort. The Tamil ethnicity is an isolated population with high prevalence of type 2 diabetes. Cultural customs have preserved this population from ethnic admixture. The first and the most of the second generation of migrated Tamils still belong to a population with a homogeneous genetic background, which facilitate to identify complex trait-susceptibility genes.
In contrast to many previous genome-wide association studies an inverse approach is taken for this study. The primary objective of this study is to show changes in the metabolic concentrations in plasma between Tamil individuals and native Swiss population using a mass-spectrometric approach. Type 2 diabetics have specific metabolic variations, and the investigators assume that South Asians and Caucasians differ in these alterations. The secondary aim of this study is to identify the key enzymes, their corresponding genes, and the respective polymorphisms relevant for the metabolic variations using a metabolic-pathway-based search including also intronic variants commonly missed by SNP (single nucleotide polymorphism)-and haplotype-analysis.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Tamil natives with Diabetes Type 2 | – | Other: Clinical examination, Other: Blood testing, Other: MRIThirty Tamil natives (15 men, 15 women), representing general Tamil diabetic cohort. |
| Swiss natives with Diabetes Type 2_matched | – | Other: Clinical examination, Other: Blood testing, Other: MRIThirty Swiss natives (15 men, 15 women) matching the Tamil cohort. |
| Swiss natives with Diabetes Type 2_not matched | – | Other: Clinical examination, Other: Blood testing, Other: MRIThirty Swiss natives (15 men, 15 women), who are not matched to the Tamil cohort, representing general Swiss diabetic cohort. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of thirty Tamils and sixty native Swiss people with type 2 diabetes.
Key inclusion criteria (4 listed)
- Diagnosed with type 2 diabetes per WHO criteria.
- Swiss ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Switzerland)
- Tamil ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Sri Lanka, belonging to ethnic identity of Tamils, respectively)
- Age limit: 18 - 75 years
Key exclusion criteria (6 listed)
- Subjects with type 1 diabetes, steroid-induced diabetes, gestation diabetes, or pancreoprivic diabetes.
- Subjects with pregnancy.
- Subjects with metal implant, tattoos, or claustrophobia. MRI must be feasible.
- Subjects with severe chronic diseases, e.g. malignancies, heart or renal diseases (> stage 3).
- Subjects not able to provide informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical examination | Other | Swiss natives with Diabetes Type 2_matched, Swiss natives with Diabetes Type 2_not matched, Tamil natives with Diabetes Type 2 |
| Blood testing | Other | Swiss natives with Diabetes Type 2_matched, Swiss natives with Diabetes Type 2_not matched, Tamil natives with Diabetes Type 2 |
| MRI | Other | Swiss natives with Diabetes Type 2_matched, Swiss natives with Diabetes Type 2_not matched, Tamil natives with Diabetes Type 2 |
Primary outcome
Metabolic phenotype of type 2 diabetes mellitus across groups
Time frame: At baseline
Significant metabolic changes in blood plasma of type 2 diabetic patients compared across groups as quantified by mass-spectrometric analysis
1 secondary outcome
Genetic Differences
Time frame: At baseline
Results and safety
The study was stopped early (reason given: Insufficient recruitment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Mar 2023.
- Background: PubMed 14671192Abate N, Carulli L, Cabo-Chan A Jr, Chandalia M, Snell PG, Grundy SM. Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. J Clin Endocrinol Metab. 2003 Dec;88(12):5927-34. doi: 10.1210/jc.2003-030453.
- Background: PubMed 16847701Barnett AH, Dixon AN, Bellary S, Hanif MW, O'hare JP, Raymond NT, Kumar S. Type 2 diabetes and cardiovascular risk in the UK south Asian community. Diabetologia. 2006 Oct;49(10):2234-46. doi: 10.1007/s00125-006-0325-1. Epub 2006 Jul 18.
- Background: PubMed 15840754Ehtisham S, Crabtree N, Clark P, Shaw N, Barrett T. Ethnic differences in insulin resistance and body composition in United Kingdom adolescents. J Clin Endocrinol Metab. 2005 Jul;90(7):3963-9. doi: 10.1210/jc.2004-2001. Epub 2005 Apr 19.
- Background: PubMed 7828231Illangasekera U, Nugegoda DB, Perera LS. Prevalence of diabetes mellitus and impaired glucose tolerance in a rural Sri Lankan community. Ceylon Med J. 1993 Sep;38(3):123-6.
- Background: PubMed 15067982Illangasekera U, Rambodagalla S, Tennakoon S. Temporal trends in the prevalence of diabetes mellitus in a rural community in Sri Lanka. J R Soc Promot Health. 2004 Mar;124(2):92-4. doi: 10.1177/146642400412400214.
- Background: PubMed 22761945Jourdan C, Petersen AK, Gieger C, Doring A, Illig T, Wang-Sattler R, Meisinger C, Peters A, Adamski J, Prehn C, Suhre K, Altmaier E, Kastenmuller G, Romisch-Margl W, Theis FJ, Krumsiek J, Wichmann HE, Linseisen J. Body fat free mass is associated with the serum metabolite profile in a population-based study. PLoS One. 2012;7(6):e40009. doi: 10.1371/journal.pone.0040009. Epub 2012 Jun 27.
- Background: PubMed 19183311Katulanda P, Constantine GR, Mahesh JG, Sheriff R, Seneviratne RD, Wijeratne S, Wijesuriya M, McCarthy MI, Adler AI, Matthews DR. Prevalence and projections of diabetes and pre-diabetes in adults in Sri Lanka--Sri Lanka Diabetes, Cardiovascular Study (SLDCS). Diabet Med. 2008 Sep;25(9):1062-9. doi: 10.1111/j.1464-5491.2008.02523.x.
- Background: PubMed 16898034Katulanda P, Sheriff MH, Matthews DR. The diabetes epidemic in Sri Lanka - a growing problem. Ceylon Med J. 2006 Mar;51(1):26-8. doi: 10.4038/cmj.v51i1.1373.
- Background: PubMed 19875164Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010 Jan 30;375(9712):408-18. doi: 10.1016/S0140-6736(09)60937-5. Epub 2009 Oct 28.
- Background: PubMed 11272168Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes. 2001 Feb;50 Suppl 1:S118-21. doi: 10.2337/diabetes.50.2007.s118.
- Background: PubMed 22167294Vandenheede H, Deboosere P, Stirbu I, Agyemang CO, Harding S, Juel K, Rafnsson SB, Regidor E, Rey G, Rosato M, Mackenbach JP, Kunst AE. Migrant mortality from diabetes mellitus across Europe: the importance of socio-economic change. Eur J Epidemiol. 2012 Feb;27(2):109-17. doi: 10.1007/s10654-011-9638-6. Epub 2011 Dec 14.
- Individual participant dataSharing planned: No. Sharing data depends on institutional (sponsor) and ethics agreement.
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Martin Fiedler, MD, MBA principal investigator
Insel Gruppe AG, University Hospital Bern
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Mellitus, Type 2, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 28 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Insufficient recruitment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Metabolic phenotype of type 2 diabetes mellitus across groups (time frame: At baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05787457, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2023.